Al Nilum's Early Stage Treatment of Alzheimer's Disease

Al Nilum is trying to silence the gene that produces amyloid precursor protein. In a phase one study, enrolling 20 patients with early onset Alzheimer's disease, Al Nilum's treatment seems to be hitting the target. The Food and Drug Administration saw something concerning in preclinical data on this very drug such that it has placed a partial clinical hold on alnilus' plans for expansion of trial.